| Nov 22 |
Ocean Biomedical receives notice from Nasdaq regarding late filing
|
| Oct 22 |
Ocean Biomedical receives Nasdaq’s delisting letter
|
| Oct 22 |
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
|
| Oct 1 |
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
|
| Aug 27 |
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms
|
| Aug 23 |
Ocean Biomedical receives non-compliance notice from Nasdaq
|
| Jun 5 |
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
|
| May 30 |
Ocean Biomedical gets non-compliance notice from Nasdaq
|
| May 30 |
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
|
